​177Lu-NRT6020 / Chengdu New Radiomedicine Technology - LARVOL DELTA

Safety Trial of 68Ga/177Lu-NRT6020 in FAP-Positive Advanced Solid Tumor Patients (clinicaltrials.gov) - P1 | N=132 | Recruiting | Sponsor: Chengdu New Radiomedicine Technology Co. LTD. | Not yet recruiting ➔ Recruiting | Initiation date: Jul 2025 ➔ Nov 2025

Enrollment open • Trial initiation date • Oncology • Solid Tumor

Exploring Synergy between 177Lu-Labeled FAP Cyclic Peptide and Oncolytic Virus in the Therapeutic Landscape of Triple-Negative Breast Cancer (SNMMI 2025) - "[68Ga]Ga/[177Lu]Lu-FAP-NRT6020 demonstrated high radiochemical purity, stability, and superior tumor retention compared to FAPI-04 and FAP-2286. PET imaging revealed higher SUVmax and T/N ratios for [68Ga]Ga-FAP-NRT6020. Therapeutic studies showed dose-dependent efficacy in inhibiting tumor growth and extending survival with minimal toxicity at optimal doses."

IO biomarker • Oncolytic virus • Breast Cancer • Infectious Disease • Oncology • Solid Tumor • Triple Negative Breast Cancer • CAFs • CD8 • FAP • IL12A